FibroBiologics is combining cannabidiol with fibroblast-based cell therapy for disc disease. Learn more to know if this approach could change regenerative treatment.

FibroBiologics has strengthened its intellectual property position in Australia with a newly accepted patent application No. 2020368344, titled Cannabidiol Adjuvant Therapy for Treatment of Disc Degenerative Disease. And it includes methods utilizing the combination of cannabidiol with fibroblasts of therapeutic value in order to help regenerate discs and safeguard injured cells.

This patent include a number of ways through which cannabidiol can be administered, which include systemic delivery, transdermal delivery and intradiscal delivery methods. This also relate to fibroblasts that are capable of being differentiated into notochord cells or chondrocytes to help replace the nucleus pulposus of the intervertebral disc.

Could Cannabidiol Help Create a Better Environment for Regeneration?

This technology is not limited to the use of cannabidiol as an independent treatment. Cannabidiol may be used in the treatment in relation to the stimulation of regeneration capacity of fibroblasts, including synthesis by these cells of growth factors like IGF-1 and EGF-1, which are linked to cell viability and remodelling of the extracellular matrix.

Degenerative disc disease affects hundreds of millions of people worldwide and can cause persistent back and neck pain, limited movement and a lower quality of life. Existing treatments of degenerative disc disease do not treat the damage but only relieve the symptoms. Fibroblasts have come into focus in regenerative medicine as a source of growth factors, as well as tissue remodelling and immunity regulator. FibroBiologics is working on the utilization of these properties of fibroblasts in the context of its cell therapy pipeline.

“Pairing cannabidiol with our fibroblast-based cell therapy is designed to protect the cells of the disc while promoting regeneration,” said Pete O’Heeron, Founder and CEO of FibroBiologics.

The Regulatory Path Will Be the Real Test

The patent acceptance strengthens the company’s position but the next challenge is translating the concept into a clinical program. Cell differentiation, manufacturing consistency, potency testing and long-term stability will all be important as development progresses. FibroBiologics says it has more than 270 issued and pending patents covering healthcare areas including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, longevity and cancer.

What Comes Next for the Therapy?

The development of the company in the future will depend on the clinical proof that this combination is safe to use in order to regenerate disc cells. The success of this project could lead to the development of an alternative treatment that is oriented at pain management mostly.

According to Business Fortune, this Australian patent victory of FibroBiologics could be a significant achievement for the company on the path to convert fibroblast therapy from intellectual property into potential treatments for chronic degenerative diseases.

 

FAQs

What did IP Australia accept from FibroBiologics?

IP Australia accepted Patent Application No. 2020368344, covering the use of cannabidiol alongside fibroblast-based cell therapy for degenerative disc disease.

What is the purpose of cannabidiol in the proposed therapy?

The patent describes cannabidiol as potentially helping protect disc cells from cell death and enhancing the regenerative activity of fibroblasts.

What are fibroblasts?

Fibroblasts are connective tissue cells that produce growth factors and help maintain and repair the extracellular matrix.

Does the patent mean the treatment is already available to patients?

No. Patent acceptance protects the claimed technology. Clinical testing and regulatory approval are still needed before any treatment could become widely available.

Why is this development important?

It expands FibroBiologics’ intellectual property around disc degeneration and supports its broader effort to develop regenerative cell therapies for chronic diseases.